Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers

Giuseppe Santini, Nadia Mores, Rugia Shohreh, Salvatore Valente, Malgorzata Dabrowska, Andrea Trové, Gina Zini, Paola Cattani, Leonello Fuso, Antonella Mautone, Chiara Mondino, Gabriella Pagliari, Angelo Sala, Giancarlo Folco, Marina Aiello, Roberta Pisi, Alfredo Chetta, Monica Losi, Enrico Clini, Giovanni CiabattoniPaolo Montuschi

Research output: Contribution to journalArticle

Abstract

We aimed at comparing exhaled and non-exhaled non-invasive markers of respiratory inflammation in patients with chronic obstructive pulmonary disease (COPD) and healthy subjects and define their relationships with smoking habit. Forty-eight patients with stable COPD who were ex-smokers, 17 patients with stable COPD who were current smokers, 12 healthy current smokers and 12 healthy ex-smokers were included in a cross-sectional, observational study. Inflammatory outcomes, including prostaglandin (PG) E2 and 15-F2t-isoprostane (15-F2t-IsoP) concentrations in exhaled breath condensate (EBC) and sputum supernatants, fraction of exhaled nitric oxide (FENO) and sputum cell counts, and functional (spirometry) outcomes were measured. Sputum PGE2 was elevated in both groups of smokers compared with ex-smoker counterpart (COPD: P  <  0.02; healthy subjects: P  <  0.03), whereas EBC PGE2 was elevated in current (P  =  0.0065) and ex-smokers with COPD (P  =  0.0029) versus healthy ex-smokers. EBC 15-F2t-IsoP, a marker of oxidative stress, was increased in current and ex-smokers with COPD (P  <  0.0001 for both) compared with healthy ex-smokers, whereas urinary 15-F2t-IsoP was elevated in both smoker groups (COPD: P  <  0.01; healthy subjects: P  <  0.02) versus healthy ex-smokers. FENO was elevated in ex-smokers with COPD versus smoker groups (P  =  0.0001 for both). These data suggest that the biological meaning of these inflammatory markers depends on type of marker and biological matrix in which is measured. An approach combining different types of outcomes can be used for assessing respiratory inflammation in patients with COPD. Large studies are required to establish the clinical utility of this strategy.

Original languageEnglish
Pages (from-to)17102
Number of pages1
JournalJournal of Breath Research
Volume10
Issue number1
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Chronic Obstructive Pulmonary Disease
Inflammation
Sputum
Dinoprostone
Healthy Volunteers
Nitric Oxide
Spirometry
Habits
Observational Studies
Oxidative Stress
Cell Count
Cross-Sectional Studies
Biomarkers
Smoking
15-F2t-isoprostane

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers. / Santini, Giuseppe; Mores, Nadia; Shohreh, Rugia; Valente, Salvatore; Dabrowska, Malgorzata; Trové, Andrea; Zini, Gina; Cattani, Paola; Fuso, Leonello; Mautone, Antonella; Mondino, Chiara; Pagliari, Gabriella; Sala, Angelo; Folco, Giancarlo; Aiello, Marina; Pisi, Roberta; Chetta, Alfredo; Losi, Monica; Clini, Enrico; Ciabattoni, Giovanni; Montuschi, Paolo.

In: Journal of Breath Research, Vol. 10, No. 1, 01.03.2016, p. 17102.

Research output: Contribution to journalArticle

Santini, G, Mores, N, Shohreh, R, Valente, S, Dabrowska, M, Trové, A, Zini, G, Cattani, P, Fuso, L, Mautone, A, Mondino, C, Pagliari, G, Sala, A, Folco, G, Aiello, M, Pisi, R, Chetta, A, Losi, M, Clini, E, Ciabattoni, G & Montuschi, P 2016, 'Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers', Journal of Breath Research, vol. 10, no. 1, pp. 17102. https://doi.org/10.1088/1752-7155/10/1/017102
Santini, Giuseppe ; Mores, Nadia ; Shohreh, Rugia ; Valente, Salvatore ; Dabrowska, Malgorzata ; Trové, Andrea ; Zini, Gina ; Cattani, Paola ; Fuso, Leonello ; Mautone, Antonella ; Mondino, Chiara ; Pagliari, Gabriella ; Sala, Angelo ; Folco, Giancarlo ; Aiello, Marina ; Pisi, Roberta ; Chetta, Alfredo ; Losi, Monica ; Clini, Enrico ; Ciabattoni, Giovanni ; Montuschi, Paolo. / Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers. In: Journal of Breath Research. 2016 ; Vol. 10, No. 1. pp. 17102.
@article{4a8f641353434152ab08335b7f926993,
title = "Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers",
abstract = "We aimed at comparing exhaled and non-exhaled non-invasive markers of respiratory inflammation in patients with chronic obstructive pulmonary disease (COPD) and healthy subjects and define their relationships with smoking habit. Forty-eight patients with stable COPD who were ex-smokers, 17 patients with stable COPD who were current smokers, 12 healthy current smokers and 12 healthy ex-smokers were included in a cross-sectional, observational study. Inflammatory outcomes, including prostaglandin (PG) E2 and 15-F2t-isoprostane (15-F2t-IsoP) concentrations in exhaled breath condensate (EBC) and sputum supernatants, fraction of exhaled nitric oxide (FENO) and sputum cell counts, and functional (spirometry) outcomes were measured. Sputum PGE2 was elevated in both groups of smokers compared with ex-smoker counterpart (COPD: P  <  0.02; healthy subjects: P  <  0.03), whereas EBC PGE2 was elevated in current (P  =  0.0065) and ex-smokers with COPD (P  =  0.0029) versus healthy ex-smokers. EBC 15-F2t-IsoP, a marker of oxidative stress, was increased in current and ex-smokers with COPD (P  <  0.0001 for both) compared with healthy ex-smokers, whereas urinary 15-F2t-IsoP was elevated in both smoker groups (COPD: P  <  0.01; healthy subjects: P  <  0.02) versus healthy ex-smokers. FENO was elevated in ex-smokers with COPD versus smoker groups (P  =  0.0001 for both). These data suggest that the biological meaning of these inflammatory markers depends on type of marker and biological matrix in which is measured. An approach combining different types of outcomes can be used for assessing respiratory inflammation in patients with COPD. Large studies are required to establish the clinical utility of this strategy.",
author = "Giuseppe Santini and Nadia Mores and Rugia Shohreh and Salvatore Valente and Malgorzata Dabrowska and Andrea Trov{\'e} and Gina Zini and Paola Cattani and Leonello Fuso and Antonella Mautone and Chiara Mondino and Gabriella Pagliari and Angelo Sala and Giancarlo Folco and Marina Aiello and Roberta Pisi and Alfredo Chetta and Monica Losi and Enrico Clini and Giovanni Ciabattoni and Paolo Montuschi",
year = "2016",
month = "3",
day = "1",
doi = "10.1088/1752-7155/10/1/017102",
language = "English",
volume = "10",
pages = "17102",
journal = "Journal of Breath Research",
issn = "1752-7155",
publisher = "IOP Publishing Ltd.",
number = "1",

}

TY - JOUR

T1 - Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers

AU - Santini, Giuseppe

AU - Mores, Nadia

AU - Shohreh, Rugia

AU - Valente, Salvatore

AU - Dabrowska, Malgorzata

AU - Trové, Andrea

AU - Zini, Gina

AU - Cattani, Paola

AU - Fuso, Leonello

AU - Mautone, Antonella

AU - Mondino, Chiara

AU - Pagliari, Gabriella

AU - Sala, Angelo

AU - Folco, Giancarlo

AU - Aiello, Marina

AU - Pisi, Roberta

AU - Chetta, Alfredo

AU - Losi, Monica

AU - Clini, Enrico

AU - Ciabattoni, Giovanni

AU - Montuschi, Paolo

PY - 2016/3/1

Y1 - 2016/3/1

N2 - We aimed at comparing exhaled and non-exhaled non-invasive markers of respiratory inflammation in patients with chronic obstructive pulmonary disease (COPD) and healthy subjects and define their relationships with smoking habit. Forty-eight patients with stable COPD who were ex-smokers, 17 patients with stable COPD who were current smokers, 12 healthy current smokers and 12 healthy ex-smokers were included in a cross-sectional, observational study. Inflammatory outcomes, including prostaglandin (PG) E2 and 15-F2t-isoprostane (15-F2t-IsoP) concentrations in exhaled breath condensate (EBC) and sputum supernatants, fraction of exhaled nitric oxide (FENO) and sputum cell counts, and functional (spirometry) outcomes were measured. Sputum PGE2 was elevated in both groups of smokers compared with ex-smoker counterpart (COPD: P  <  0.02; healthy subjects: P  <  0.03), whereas EBC PGE2 was elevated in current (P  =  0.0065) and ex-smokers with COPD (P  =  0.0029) versus healthy ex-smokers. EBC 15-F2t-IsoP, a marker of oxidative stress, was increased in current and ex-smokers with COPD (P  <  0.0001 for both) compared with healthy ex-smokers, whereas urinary 15-F2t-IsoP was elevated in both smoker groups (COPD: P  <  0.01; healthy subjects: P  <  0.02) versus healthy ex-smokers. FENO was elevated in ex-smokers with COPD versus smoker groups (P  =  0.0001 for both). These data suggest that the biological meaning of these inflammatory markers depends on type of marker and biological matrix in which is measured. An approach combining different types of outcomes can be used for assessing respiratory inflammation in patients with COPD. Large studies are required to establish the clinical utility of this strategy.

AB - We aimed at comparing exhaled and non-exhaled non-invasive markers of respiratory inflammation in patients with chronic obstructive pulmonary disease (COPD) and healthy subjects and define their relationships with smoking habit. Forty-eight patients with stable COPD who were ex-smokers, 17 patients with stable COPD who were current smokers, 12 healthy current smokers and 12 healthy ex-smokers were included in a cross-sectional, observational study. Inflammatory outcomes, including prostaglandin (PG) E2 and 15-F2t-isoprostane (15-F2t-IsoP) concentrations in exhaled breath condensate (EBC) and sputum supernatants, fraction of exhaled nitric oxide (FENO) and sputum cell counts, and functional (spirometry) outcomes were measured. Sputum PGE2 was elevated in both groups of smokers compared with ex-smoker counterpart (COPD: P  <  0.02; healthy subjects: P  <  0.03), whereas EBC PGE2 was elevated in current (P  =  0.0065) and ex-smokers with COPD (P  =  0.0029) versus healthy ex-smokers. EBC 15-F2t-IsoP, a marker of oxidative stress, was increased in current and ex-smokers with COPD (P  <  0.0001 for both) compared with healthy ex-smokers, whereas urinary 15-F2t-IsoP was elevated in both smoker groups (COPD: P  <  0.01; healthy subjects: P  <  0.02) versus healthy ex-smokers. FENO was elevated in ex-smokers with COPD versus smoker groups (P  =  0.0001 for both). These data suggest that the biological meaning of these inflammatory markers depends on type of marker and biological matrix in which is measured. An approach combining different types of outcomes can be used for assessing respiratory inflammation in patients with COPD. Large studies are required to establish the clinical utility of this strategy.

UR - http://www.scopus.com/inward/record.url?scp=84984782926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984782926&partnerID=8YFLogxK

U2 - 10.1088/1752-7155/10/1/017102

DO - 10.1088/1752-7155/10/1/017102

M3 - Article

C2 - 26814886

AN - SCOPUS:84962422657

VL - 10

SP - 17102

JO - Journal of Breath Research

JF - Journal of Breath Research

SN - 1752-7155

IS - 1

ER -